Albiglutide
Also known as: Tanzeum, Eperzan
Albiglutide is a long-acting GLP-1 receptor agonist made by fusing two DPP-4-resistant copies of modified human GLP-1 to recombinant human albumin, activating the GLP-1 receptor to boost glucose-dependent insulin secretion and suppress glucagon.
- Drug class
- GLP-1 receptor agonist (albumin-fusion)
- Primary targets
- GLP-1 receptor
- Dose reference
- Per the discontinued Tanzeum label: 30 mg once weekly subcutaneously, increasable to 50 mg once weekly (historical reference, not a recommendation)
- Half-life
- Approximately 5 days (reported terminal estimates ~5-8 days)
- Developer / origin
- GlaxoSmithKline (albumin-fusion technology originated at Human Genome Sciences)
- Reference year
- 2014
- Evidence score
- 4/5 - Approved (later withdrawn); strong outcomes evidence
Approved uses
- Type 2 diabetes (FDA approval later commercially withdrawn)
Approved (later withdrawn); strong outcomes evidence
Albiglutide was FDA- and EMA-approved for type 2 diabetes glycemic control based on the eight-trial Phase 3 HARMONY program and demonstrated a 22% reduction in major adverse cardiovascular events in the 9,463-patient HARMONY Outcomes trial, but it was voluntarily withdrawn from the worldwide market in 2018 for commercial reasons.
Investigational compound with human randomized or phase 2/3 evidence.
Evidence basis
- FDA prescribing information (Tanzeum) documenting approval, dosing, and boxed warning
- HARMONY Outcomes randomized placebo-controlled cardiovascular trial published in The Lancet (2018), NCT02465515
- Phase 3 HARMONY program of eight trials supporting approval
- Manufacturer and FDA records of 2014 approval and 2017-2018 market withdrawal
Key references
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Albiglutide guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Retatrutide
LY3437943
Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.
Tirzepatide
LY3298176, Mounjaro, Zepbound
Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.
Semaglutide
Ozempic, Wegovy, Rybelsus
Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.
Liraglutide
Victoza, Saxenda
Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.
Category hub
Open the category page for the full comparison table and FAQ.